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Previews
The patients in this double-blind study received eitherHints of a Therapeutic Vaccine
preaggregated synthetic A42 with the saponin QS-21for Alzheimer’s? as an adjuvant to stimulate a vigorous immune response
or placebo in two injections separated by 1 month. The
-amyloid/placebo status of the patients is still unknown
to the authors. What was assayed was the antibodyIn this issue of Neuron, Hock et al. report the cognitive
production of the patients. Serum samples were takenfunctions of a small number of Alzheimer’s disease
from the patients before and 12 months after treatment,patients that participated in a clinical trial of immuniza-
and -amyloid immunoreactivity was assayed on fixedtion with -amyloid. Patients with serum antibodies
brains from a mouse model of AD that producesagainst -amyloid plaques showed a diminished cog-
-amyloid plaques. This test is called the tissue amyloidnitive decline and slowed disease progression. Dan-
plaque immunoreactivity (TAPIR) assay.gerous meningoencephalitis was present in some pa-
Patients who produced antibodies in the TAPIR assaytients, as has been previously reported.
showed less cognitive decline over the course of 1 year
than those who did not produce antibodies. This correla-Many mechanistic insights into the etiology and patho-
tion was found for several standard tests, including thegenesis of Alzheimer’s disease have been gained in re-
Mini Mental State Examination (which combines assayscent years. As with other polygenic disorders, a minority
of several aspects of cognitive status, including orienta-of cases appear directly linked to specific gene muta-
tion, attention, recall, language, and the ability to followtions, and it has been hoped that the biological insights
simple commands), Disability Assessment for Dementiagained from those cases can be leveraged to address
(which assays basic self-care and instrumental activitiesthe sporadic cases, which are the majority. A central
of daily living), and the visual delayed recall test fromidea that has emerged in this fashion has been that
the Wechsler Memory Scale. Thus, the clinical benefitsdysfunctional processing of the amyloid precursor pro-
appear to cover a wide spectrum of cognitive functionstein APP drives disease pathology in familial Alzheimer’s
that are attacked in Alzheimer’s disease, from memorydisease (FAD) and perhaps even late-onset Alzheimer’s
to daily self-care.
disease (LOAD). In this issue of Neuron, Hock et al.
In the evaluation of the clinical significance, the au-
(2003) report a significant reduction of the cognitive de-
thors are presenting data on prevention of disease pro-
cline in patients with Alzheimer’s disease who partici-
gression or even disease arrest by using the MMSE
pated in an immunization protocol involving aggregated
scores. A normal decline in MMSE score over 1 year in
A42. These results provide support for the proposal
an Alzheimer population is around 3 points and in clinical
that this -amyloid peptide is a key driver of pathology trials with cholinergic drugs somewhat lower (Aguero-
in Alzheimer’s disease. There is the suggestion, as well, Torres et al., 1998). In the present report by Hock et al.,
that if safety issues can be addressed, a vaccine ap- patients without immune response (9 patients) worsened
proach will prove to have important therapeutic value. significantly by 6.3  4.0 points on the MMSE scale
A very strong note of caution must be sounded, how- after 1 year. This decline is larger than typical, which
ever, about the therapeutic implications. These patients again points to the need to confirm the findings when
comprised the Zurich cohort of the larger ELAN/Wyeth- the data from the larger study are analyzed. The authors
Ayerst AN1792(QS-21) Phase IIA multicenter trial. That also point out that their TAPIR assay appears to produce
trial received widespread press coverage when all study a tighter correlation with cognitive efficacy than ELISA.
dosing was halted in January of 2002 because 17 of They raise the possibility that a functional immune re-
the 300 study patients who were immunized developed sponse is related to the development of conformation-
aseptic meningoencephalitis (Schenk, 2002). This re- specific antibodies. It is unclear at this point if TAPIR
sponse has not been successfully treated in all cases. will be compatible with modified ELISA assays.
Thus, while there are hopes that it can be mitigated or Since it is likely that many of the AD cases in this
eliminated, this potentially fatal side effect remains an cohort suffered from LOAD (given age and severity), it
overriding concern. appears possible that the treatment may be effective in
The study reported by Hock et al. is very small. A total sporadic AD cases, which are the majority. Thus, even
of 30 patients were included in this particular cohort, in those cases where mutant-amyloid is not an obvious
less than 10% of the number involved in the full multicen- culprit, antibody production against it appears to have
ter trial of which this cohort was a part. Only 6 of the beneficial effect. On the other hand, since there is no
30 patients received placebo. With a small sample, the clear sign that the treatment actually reverses cognitive
chances of false positive results increase and there is deficits within 1 year, it may be that there is residual
a greater likelihood that some systematic error will bias damage, whether from tau pathology, synapse or neuron
the results. For example, the patient sample could be degeneration, or otherwise, that may be irreversible, at
biased by personal history, medical history, or genotype. least by attacking -amyloid.
Thus, while the results are statistically significant, it will The effects of antibody production are impressive and
be important to confirm that they hold up with a much the findings presented are important in providing further
larger sample size. In this sense the results should be evidence for the validity of the prevailing working hy-
pothesis, the Amyloid Cascade Hypothesis. So far, theregarded as preliminary.
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findings are of great interest from a scientific perspec- (AMG), orbitofrontal cortex (OFC), and prefrontal cortex
(PFC) during the learning and performance of contextu-tive, but they are also clearly important from a clinical
ally appropriate behavior (Alexander et al., 1990).and societal perspective. Even though the meningoen-
Current models posit that learning occurs following acephalitis side effect remains a problem, this article
mismatch in the response of midbrain dopamine neu-shows that the concept of vaccination is alive.
rons to cues that predict rewards and actual reward
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formed during learning and how they change when pre-
dictions fail, particularly in contexts involving both aver-Selected Reading
sive and rewarding outcomes. In this issue of Neuron,
Aguero-Torres, H., Fratiglioni, L., and Winblad, B. (1998). Int. J. Geri- Setlow and colleagues extend prior investigations of
atr. Psychiatry 13, 755–766. neural encoding in VS by examining neural responses
Hock, C., Konietzko, U., Streffer, J.R., Tracy, J., Signorell, A., Muller- and behavior during cue learning involving both re-
Tillmanns, B., Lemke, U., Henke, K., Moritz, E., Garcia, E., et al. warding and aversive outcomes. Their data suggest that
(2003). Neuron 38, this issue, 547–554. VS processes cues associated with both aversive and
Schenk, D. (2002). Nat. Rev. Neurosci. 3, 824–828. rewarding outcomes and that selective neuronal re-
sponses in this area evolve over time in a fashion roughly
paralleling learned behavior (Setlow et al., 2003). These
data powerfully document the role of VS in linking envi-
ronmental stimuli with biologically significant outcomesLearning Is Bitter and Sweet
during learning.
in Ventral Striatum In this study, Setlow and colleagues used an olfactory
go/no-go task that required rats to learn to discriminate
two odors, one of which predicted a palatable sucrose
solution in the drinking well (positive odor) and anotherThe ventral striatum (VS) plays a key role in motivation-
which predicted a bitter quinine solution (negative odor).ally guided learning. Setlow et al. show that VS neurons
The rat’s job was to learn the significance of the odorencode the significance of cues associated with both
cues and drink following presentation of the positiveaversive and rewarding outcomes and that this neural
odor and avoid drinking following presentation of thelinkage develops over time in a fashion roughly paral-
negative odor. Behavioral performance, as well as neu-leling the expression of learned behavior. Subpopula-
ronal activity in VS, including both the core region of thetions of VS neurons may contribute distinct signals to
nucleus accumbens and the ventral caudate-putamen,
the learning process, reflecting either cue significance
was recorded during learning. In a further set of experi-
or learned sensory-motor associations. mental sessions, behavior and neuronal activity were
recorded following reversal of odor-outcome pairings.
Back in the early 1990s, Michael Stipe of the band R.E.M. Rats rapidly learned the significance of the odor cues,
wryly crooned “your head is there to move you around.” performing better than 90% correct within 100 trials
Without a means for modifying movement in response of odor-outcome pairing. Moreover, rats were faster to
to changing external conditions and internal milieu, how- begin drinking from the fluid well on positive odor trials
ever, Stipe’s “head” would be useless. Not surprisingly, than when they erroneously drank on negative odor tri-
animals with even the simplest of nervous systems have als, and these differences in response latency became
evolved mechanisms for assessing the outcome, either more pronounced with experience. Changes in discrimi-
good or bad, of behavior and linking these outcomes nation accuracy were not closely related to changes in
to salient cues in the environment. By potentiating re- response latency, suggesting that these two behavioral
sponses to cues associated with good outcomes and measures might reflect different components of the
inhibiting responses to cues associated with bad out- learning process.
comes, the nervous system adapts behavior to the cur- The authors also found that, once rats had mastered
rent environment and thereby achieves a positive inter- the odor discrimination, about 40% of neurons in the
nal milieu (Thorndike, 1898). In mammals, this type of VS responded differentially to the two odor cues. Intrigu-
motivationally guided learning involves neural circuits ingly, about 1/4 responded more strongly to odors pre-
within the basal ganglia, including the dorsal and ventral dicting sucrose, and about 3/4 responded more strongly
striatum (VS), as well as inputs to these nuclei from to odors predicting quinine. These neuronal responses
dopaminergic neurons in the midbrain ventral tegmental did not merely reflect impending behavior, i.e., withhold-
area (VTA) and substantia nigra pars compacta (SNC; ing or initiating drinking, suggesting that VS neurons
reviewed in Schultz, 2002). In turn, these circuits partici- encode the motivational significance of behavioral cues
rather than a planned or anticipated movement.pate in larger signaling loops involving the amygdala
